AOD-9604 research guide

AOD-9604 in Alnif — Fat Loss Peptide Research Guide

AOD-9604 research guide for Alnif. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Finding AOD-9604 in Alnif

For anyone in Alnif looking to source AOD-9604, the first thing to know is that this compound moves through online research channels. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any physical store could provide. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide walks Alnif researchers through that evaluation process and explains the signals that distinguish quality AOD-9604 suppliers.

AOD-9604: What the Research Shows

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Alnif comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.

Buying AOD-9604: Quality Markers to Look For

The first step for any Alnif researcher sourcing AOD-9604 is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. The combination of peer feedback and direct document verification is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. Store lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.

Order AOD-9604 — ships to Alnif
COA-verified · International tracking · Research grade
Order Now →

Safe Research Practices for AOD-9604

Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Proper handling of AOD-9604 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and cold chain maintenance from receipt through use. Verify the endotoxin level in your AOD-9604 batch COA before any injectable research application — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. Protocol documentation — recording exactly what was used, when, and how — is a fundamental research principle that allows any unexpected observations to be properly contextualised.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →